Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “hold” rating reiterated by research analysts at Stifel Nicolaus in a research note issued on Wednesday. They presently have a $83.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $56.00. Stifel Nicolaus’ price objective points to a potential downside of 27.05% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Needham & Company LLC lifted their price target on shares of Alnylam Pharmaceuticals from $85.00 to $125.00 in a research note on Wednesday. Chardan Capital set a $110.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, June 12th. Jefferies Group LLC reissued a “buy” rating and set a $102.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, June 22nd. BidaskClub downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 29th. Finally, Piper Jaffray Companies set a $116.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 24th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company. Alnylam Pharmaceuticals has an average rating of “Hold” and a consensus target price of $87.59.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded up 51.71% during midday trading on Wednesday, hitting $113.84. 18,362,421 shares of the stock were exchanged. The company’s market cap is $10.44 billion. Alnylam Pharmaceuticals has a 12 month low of $31.38 and a 12 month high of $116.93. The stock has a 50 day moving average price of $81.14 and a 200-day moving average price of $69.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. During the same quarter in the prior year, the business earned ($1.05) earnings per share. Alnylam Pharmaceuticals’s revenue was up 82.9% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals will post ($5.19) EPS for the current year.

WARNING: “Alnylam Pharmaceuticals’ (ALNY) “Hold” Rating Reaffirmed at Stifel Nicolaus” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/20/alnylam-pharmaceuticals-alny-hold-rating-reaffirmed-at-stifel-nicolaus.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC lifted its stake in shares of Alnylam Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after purchasing an additional 815,270 shares during the period. Wellington Management Group LLP lifted its stake in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock valued at $617,111,000 after purchasing an additional 31,208 shares during the period. Vanguard Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 13.4% in the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after purchasing an additional 759,295 shares during the period. BlackRock Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 9.3% in the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock valued at $413,811,000 after purchasing an additional 441,957 shares during the period. Finally, Baillie Gifford & Co. lifted its stake in shares of Alnylam Pharmaceuticals by 2.9% in the second quarter. Baillie Gifford & Co. now owns 3,431,316 shares of the biopharmaceutical company’s stock valued at $273,681,000 after purchasing an additional 96,805 shares during the period. Hedge funds and other institutional investors own 94.25% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.